» Articles » PMID: 24851944

Intra-subtype Variation in Enteroadhesion Accounts for Differences in Epithelial Barrier Disruption and is Associated with Metronidazole Resistance in Blastocystis Subtype-7

Overview
Date 2014 May 24
PMID 24851944
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Blastocystis is an extracellular, enteric pathogen that induces intestinal disorders in a range of hosts including humans. Recent studies have identified potential parasite virulence factors in and host responses to this parasite; however, little is known about Blastocystis-host attachment, which is crucial for colonization and virulence of luminal stages. By utilizing 7 different strains of the parasite belonging to two clinically relevant subtypes ST-4 and ST-7, we investigated Blastocystis-enterocyte adhesion and its association with parasite-induced epithelial barrier disruption. We also suggest that drug resistance in ST-7 strains might result in fitness cost that manifested as impairment of parasite adhesion and, consequently, virulence. ST-7 parasites were generally highly adhesive to Caco-2 cells and preferred binding to intercellular junctions. These strains also induced disruption of ZO-1 and occludin tight junction proteins as well as increased dextran-FITC flux across epithelial monolayers. Interestingly, their adhesion was correlated with metronidazole (Mz) susceptibility. Mz resistant (Mzr) strains were found to be less pathogenic, owing to compromised adhesion. Moreover, tolerance of nitrosative stress was also reduced in the Mzr strains. In conclusion, the findings indicate that Blastocystis attaches to intestinal epithelium and leads to epithelial barrier dysfunction and that drug resistance might entail a fitness cost in parasite virulence by limiting entero-adhesiveness. This is the first study of the cellular basis for strain-to-strain variation in parasite pathogenicity. Intra- and inter-subtype variability in cytopathogenicity provides a possible explanation for the diverse clinical outcomes of Blastocystis infections.

Citing Articles

Prevalence and subtypes of in wild rodents from three provinces in China.

Gao Z, Wang H, Hou Q, Qin Y, Yang X, Zhao Q Front Vet Sci. 2024; 11:1432741.

PMID: 39071781 PMC: 11274486. DOI: 10.3389/fvets.2024.1432741.


A mitochondrial carrier transports glycolytic intermediates to link cytosolic and mitochondrial glycolysis in the human gut parasite .

Pyrihova E, King M, King A, Toleco M, van der Giezen M, Kunji E Elife. 2024; 13.

PMID: 38780415 PMC: 11115451. DOI: 10.7554/eLife.94187.


The influence of plant extracts on viability of ST3 and ST7 subtypes of Blastocystis sp.

Kot K, Michaliszyn A, Kalisinska E, Lepczynska M Gut Pathog. 2024; 16(1):19.

PMID: 38570865 PMC: 10988960. DOI: 10.1186/s13099-024-00613-z.


Green synthesis of silver and iron oxide nanoparticles mediated photothermal effects on Blastocystis hominis.

Alexeree S, Abou-Seri H, El-Din H, Youssef D, Ramadan M Lasers Med Sci. 2024; 39(1):43.

PMID: 38246979 PMC: 10800310. DOI: 10.1007/s10103-024-03984-6.


Interactions between Balantidium ctenopharyngodoni and microbiota reveal its low pathogenicity in the hindgut of grass carp.

Zhao W, Bu X, Zhou W, Zeng Q, Qin T, Wu S BMC Microbiol. 2024; 24(1):7.

PMID: 38172646 PMC: 10762984. DOI: 10.1186/s12866-023-03154-8.


References
1.
Klein U, Pawelzik M, Opferkuch W . Influence of beta-lactam antibiotics, fosfomycin and vancomycin on the adherence (hemagglutination) of Escherichia coli-containing different adhesins. Chemotherapy. 1985; 31(2):138-45. DOI: 10.1159/000238326. View

2.
Eida O, Hussein E, Eida A, El-Moamly A, Salem A . Evaluation of the nitric oxide activity against Blastocystis hominis in vitro and in vivo. J Egypt Soc Parasitol. 2008; 38(2):521-36. View

3.
Sebbane F, Lemaitre N, Sturdevant D, Rebeil R, Virtaneva K, Porcella S . Adaptive response of Yersinia pestis to extracellular effectors of innate immunity during bubonic plague. Proc Natl Acad Sci U S A. 2006; 103(31):11766-71. PMC: 1518801. DOI: 10.1073/pnas.0601182103. View

4.
van Hellemond J, Molhoek N, Koelewijn R, Wismans P, van Genderen P . Is paromomycin the drug of choice for eradication of Blastocystis in adults?. J Infect Chemother. 2012; 19(3):545-8. DOI: 10.1007/s10156-012-0496-2. View

5.
Alfellani M, Taner-Mulla D, Jacob A, Imeede C, Yoshikawa H, Stensvold C . Genetic diversity of blastocystis in livestock and zoo animals. Protist. 2013; 164(4):497-509. DOI: 10.1016/j.protis.2013.05.003. View